by Raynovich Rod | Nov 4, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update at Close 11/9/18 Remain Cautious as Rally Fails The NASDAQ down 1.6% and Russell 2000 down 1.8%, sold off killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. The healthcare still looks good overall with the XLV...
by Raynovich Rod | Oct 4, 2018 | Biopharmaceuticals, Macro
Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers...
by Raynovich Rod | Aug 31, 2018 | Biopharmaceuticals
9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down...
by Raynovich Rod | Aug 9, 2018 | Biopharmaceuticals
Update-2… 8/12 Biotech and Healthcare Holds on Emerging Market Down Day IBB down 0.55%, XBI down 0.43%, XLV down 0.43% EEM down 2.13%, QQQ down 0.76%. ==== Update-1 Rally Fades a Bit into the Close Biotech stocks were mixed trading closer to the flatline after...
by Raynovich Rod | Jul 17, 2018 | Biopharmaceuticals
Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck...
by Raynovich Rod | Jul 7, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late...
by Raynovich Rod | Jun 21, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Momentous Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170...
by Raynovich Rod | Jun 10, 2018 | Biopharmaceuticals
Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60, EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature...
by Raynovich Rod | Jun 3, 2018 | Biopharmaceuticals
6/4/18…after close Update-2…IBB down 0.65%, XBI down 0.22%. Momentum Waning Big Winners Today : BLUE, FMI, GHDX, IMMU, MRK It would appear that biotech stocks need to be bought prior to ASCO as has been then trend in the past i.e sell before the news....
by Raynovich Rod | May 29, 2018 | Biopharmaceuticals
Updates 5/30 Pre-ASCO Rally: XBI regains momentum to $94 level. IBB breaks through SMA 200 level to $108+. Many mid-caps from our watch list soaring-CRSP*, FMI, FOLD, LGND, LOXO, NKTR, SGEN, SRPT etc. *Note CRSP got whacked after hours down 13 points! The FDA has put...
